Menopause — MCQs

Menopause Indian Medical PG Practice Questions and MCQs

Question 61: What is the first-line treatment for postmenopausal osteoporosis?

A. Raloxifene
B. Tamoxifene
C. Estrogen
D. Alendronate (Correct Answer)

Explanation: **Explanation:** **1. Why Alendronate is the Correct Answer:** Bisphosphonates, specifically **Alendronate**, are considered the **first-line pharmacological treatment** for postmenopausal osteoporosis. They work by inhibiting osteoclast-mediated bone resorption, thereby increasing Bone Mineral Density (BMD) and significantly reducing the risk of both vertebral and hip fractures. According to current clinical guidelines (AACE/ACE), they are preferred due to their proven efficacy, long-term safety profile, and cost-effectiveness. **2. Why the Other Options are Incorrect:** * **Raloxifene (Option A):** This is a Selective Estrogen Receptor Modulator (SERM). While it reduces the risk of vertebral fractures and provides protection against breast cancer, it is less effective than bisphosphonates and does **not** significantly reduce the risk of non-vertebral or hip fractures. * **Tamoxifene (Option B):** Though it has estrogenic effects on bone, it is primarily used in the management of breast cancer. It is not indicated as a primary treatment for osteoporosis due to its side effect profile (e.g., risk of endometrial hyperplasia). * **Estrogen (Option C):** While Menopausal Hormone Therapy (MHT) is highly effective at preventing bone loss, it is no longer recommended as a first-line treatment for osteoporosis alone due to the associated risks of cardiovascular events and breast cancer. It is generally reserved for women who also have moderate-to-severe vasomotor symptoms. **3. High-Yield Clinical Pearls for NEET-PG:** * **Administration:** Alendronate must be taken on an empty stomach with a full glass of water, and the patient must remain upright for 30 minutes to prevent **pill-induced esophagitis**. * **Gold Standard Diagnosis:** Dual-energy X-ray Absorptiometry (DEXA) scan. Osteoporosis is defined as a **T-score ≤ -2.5**. * **Contraindications:** Bisphosphonates should be avoided in patients with chronic kidney disease (CrCl < 35 mL/min) or esophageal disorders. * **Rare Side Effects:** Osteonecrosis of the Jaw (ONJ) and atypical femoral fractures (associated with long-term use).

Question 62: Hormone replacement therapy is helpful in all of the following conditions except:

A. Vaginal atrophy
B. Flushing
C. Osteoporosis
D. Coronary heart disease (Correct Answer)

Explanation: **Explanation:** The correct answer is **Coronary Heart Disease (CHD)**. While estrogen was historically thought to be cardioprotective, major clinical trials like the **Women’s Health Initiative (WHI)** demonstrated that Hormone Replacement Therapy (HRT) does not provide primary or secondary protection against CHD. In fact, initiating HRT in older postmenopausal women (especially those >10 years past menopause) may actually **increase** the risk of coronary events and thromboembolism. **Why the other options are incorrect:** * **Vaginal Atrophy:** Estrogen is the most effective treatment for genitourinary syndrome of menopause (GSM). It restores vaginal pH, increases lubrication, and thickens the epithelium. * **Flushing (Vasomotor Symptoms):** HRT is the "gold standard" for treating hot flashes and night sweats, significantly reducing their frequency and severity by stabilizing the thermoregulatory center in the hypothalamus. * **Osteoporosis:** Estrogen inhibits osteoclast activity. HRT is highly effective in preventing bone loss and reducing the risk of hip and vertebral fractures in postmenopausal women. **High-Yield Clinical Pearls for NEET-PG:** * **The "Window of Opportunity" Hypothesis:** HRT is safest and most beneficial when started in women **<60 years old** or within **10 years** of menopause onset. * **Contraindications to HRT:** Undiagnosed vaginal bleeding, active liver disease, history of breast cancer, endometrial cancer, and history of DVT/PE or stroke. * **Progesterone Addition:** In women with an intact uterus, progesterone must always be added to estrogen to prevent **endometrial hyperplasia/carcinoma**. * **Route:** Transdermal HRT is preferred in patients with hypertension or high triglycerides as it bypasses the first-pass hepatic metabolism.

Question 63: What is the cutoff point of serum estrogen level for the diagnosis of ovarian failure?

A. 10 pg/ml
B. 20 pg/ml (Correct Answer)
C. 30 pg/ml
D. 40 pg/ml

Explanation: **Explanation:** The diagnosis of ovarian failure (menopause) is primarily clinical, defined by 12 months of amenorrhea. However, biochemical confirmation is often required, especially in cases of Premature Ovarian Failure (POF). **Why 20 pg/ml is correct:** In a functioning ovary, estradiol (E2) levels fluctuate but generally remain above 40–50 pg/ml. As ovarian follicles deplete, the production of estrogen declines significantly. A serum estradiol level **< 20 pg/ml** is the standard biochemical cutoff indicating that the ovaries are no longer producing sufficient estrogen to maintain the endometrial cycle, confirming ovarian failure. **Analysis of Incorrect Options:** * **10 pg/ml (Option A):** While levels can drop this low in late menopause, it is not the diagnostic threshold. 20 pg/ml is the recognized upper limit for the "low estrogen" state of menopause. * **30 pg/ml & 40 pg/ml (Options C & D):** These levels are too high for a diagnosis of failure. Levels between 30–50 pg/ml are often seen in the perimenopausal transition but do not signify complete ovarian shutdown. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Hormone for Diagnosis:** Serum **FSH** is the most reliable marker. A value **> 40 IU/L** (on two occasions, 4 weeks apart) is diagnostic of menopause. * **FSH/LH Ratio:** In menopause, both rise, but FSH rises more significantly than LH (FSH > LH). * **Inhibin B:** This is the earliest marker to decline in ovarian aging, even before FSH starts to rise. * **Anti-Müllerian Hormone (AMH):** The best marker for "ovarian reserve," which decreases significantly years before the actual onset of menopause.

Question 64: Identify the condition that is least likely to cause postmenopausal bleeding?

A. Genital tract trauma
B. Endometrial CA
C. Granulosa cell tumor
D. Ovarian follicular cyst (Correct Answer)

Explanation: ***Ovarian follicular cyst*** * **Follicular cysts** result from failed ovulation and require active high **FSH** stimulation, making them generally rare or transient findings in **postmenopausal** women due to ovarian senescence. * Unlike other estrogen-producing tumors, simple follicular cysts usually do not produce sufficient sustained **estrogen** levels to pathologically stimulate the endometrium and cause bleeding in the postmenopausal period. *Endometrial CA* * **Endometrial carcinoma** is the most common cause of postmenopausal bleeding, accounting for 10-15% of cases, and must be ruled out in every patient presenting with this symptom. * Bleeding results from the erosion, ulceration, and breakdown of the friable, neoplastic tissue lining the **endometrium**. *Granulosa cell tumor* * This is a classic example of an **estrogen-producing ovarian tumor** (a sex cord-stromal tumor). * The chronic, unopposed **estrogen** stimulation causes proliferation of the endometrium, leading to subsequent **endometrial hyperplasia** or cancer, resulting in bleeding. *Genital tract trauma* * Trauma, including minor injuries, is a significant cause of postmenopausal bleeding due to underlying **vaginal and cervical atrophy**. * Postmenopausal tissue is thin, lacks pliancy, and is fragile, making it susceptible to bleeding even from minor trauma during examination, intercourse, or other physical contact.

Question 65: A 60-year-old woman presents with postmenopausal bleeding per vaginum. Both per vaginum and per speculum examination reveal no abnormality, and the Pap smear is normal. What will be the most appropriate management?

A. Keep her under observation
B. Administer haemostatics
C. Measure endometrial thickness with ultrasound (Correct Answer)
D. Hysterectomy

Explanation: ***Measure endometrial thickness with ultrasound*** - **Postmenopausal bleeding (PMB)** is a significant symptom that requires thorough evaluation to rule out **endometrial hyperplasia** or **carcinoma**, even with normal clinical exams and Pap smear. - Measuring **endometrial thickness with transvaginal ultrasound (TVS)** is the **first-line investigation** for PMB to assess for abnormalities. - **Endometrial thickness >4-5mm** warrants further evaluation with **endometrial biopsy** to rule out malignancy. - This is a non-invasive, cost-effective screening tool with high sensitivity for detecting endometrial pathology. *Keep her under observation* - This approach is inappropriate for PMB, as **10-15% of cases** can indicate underlying serious pathology like **endometrial cancer**. - **Prompt investigation** is necessary to ensure timely diagnosis and treatment. - Observation without investigation can lead to dangerous delays in cancer diagnosis. *Administer haemostatics* - Administering haemostatics addresses the symptom (bleeding) but does not identify or treat the underlying cause, which could be malignant. - This would delay crucial diagnostic evaluation and potentially worsen the prognosis if a **malignant condition** is present. - **PMB always requires investigation**, not symptomatic treatment alone. *Hysterectomy* - Hysterectomy is an invasive surgical procedure and is considered a definitive treatment, not a diagnostic step in this initial presentation. - It would only be contemplated after a definitive diagnosis of a serious condition, such as **endometrial cancer**, is made via less invasive means (e.g., endometrial biopsy). - Diagnostic workup should proceed stepwise: **TVS → endometrial biopsy → treatment decision**.

Question 66: A 50 year old postmenopausal woman comes with complaints of bleeding per vaginum. Which one of the following investigations is NOT required?

A. Hysteroscopy
B. Diagnostic laparoscopy (Correct Answer)
C. Pap smear
D. Endometrial biopsy

Explanation: ***Diagnostic laparoscopy*** - **Diagnostic laparoscopy** is NOT indicated in the routine workup of **postmenopausal bleeding** as it does not allow direct visualization of the **endometrial cavity**, which is the primary site of pathology in PMB. - It is an invasive surgical procedure used to visualize pelvic and abdominal organs **externally** and is reserved for evaluating conditions like **endometriosis**, **pelvic inflammatory disease**, **adnexal masses**, or **ectopic pregnancy**. - The key investigations for PMB focus on evaluating the **endometrium** and **cervix**, not the peritoneal cavity or external surface of pelvic organs. *Hysteroscopy* - **Hysteroscopy** involves direct visualization of the **uterine cavity** and is crucial for identifying and biopsying focal lesions like **polyps**, **submucosal fibroids**, or **endometrial cancer** that can cause postmenopausal bleeding. - It allows for targeted biopsy of suspicious areas that might be missed by blind endometrial sampling. *Pap smear* - A **Pap smear** is essential for screening for **cervical cancer** and **precancerous lesions** of the cervix, which can present as postmenopausal bleeding. - Although it primarily screens the cervix, abnormal cytology indicates the need for further investigation with colposcopy and biopsy. *Endometrial biopsy* - **Endometrial biopsy** is the **gold standard** for investigating postmenopausal bleeding, as the most common cause is **endometrial cancer** or **hyperplasia**. - It provides histological samples of the endometrium to rule out malignancy and confirm benign causes like **atrophic endometrium**.

Question 67: A 30-year-old housewife reports with 6 months amenorrhea. Her serum LH and FSH are high with low estradiol levels. What is the most likely cause of amenorrhea in this context?

A. Premature menopause (Correct Answer)
B. Polycystic ovarian disease
C. Exercise induced
D. Pituitary tumour

Explanation: ***Premature menopause*** - **High LH and FSH** with **low estradiol** levels indicate primary ovarian failure, where the ovaries are no longer responding to pituitary stimulation. - In a 30-year-old woman, this ovarian failure presenting as 6 months of amenorrhea is consistent with **premature menopause** (also known as premature ovarian insufficiency). *Polycystic ovarian disease* - Characterized by **high LH:FSH ratio** (typically LH higher than FSH) and **high estrogen** due to peripheral conversion of androgens, which is contrary to the low estradiol observed here. - Presents with features like **hirsutism**, acne, and menstrual irregularities, but typically not with primary ovarian failure. *Exercise induced* - **Exercise-induced amenorrhea** (hypothalamic amenorrhea) is characterized by **low or normal LH and FSH** and **low estradiol**, reflecting inadequate GnRH pulsatility from the hypothalamus, not primary ovarian failure. - This condition is a form of **secondary amenorrhea** due to a disruption in the hypothalamic-pituitary-ovarian axis, often seen in athletes or people with low body fat. *Pituitary tumour* - A **pituitary tumor** can cause amenorrhea by various mechanisms, such as secreting prolactin (prolactinoma) which **inhibits GnRH**, leading to **low LH, FSH, and estradiol**. - Alternatively, a large non-functional tumor might cause hypopituitarism, also resulting in **low gonadotropins and estradiol**, which contradicts the high LH and FSH seen in this patient.

Question 68: Which of the undermentioned conditions does not cause postmenopausal vaginal bleeding?

A. Carcinoma of cervix
B. Senile vaginitis
C. Prolapse of uterus with decubitus ulcer
D. Benign cystic teratoma of ovary (Correct Answer)

Explanation: ***Benign cystic teratoma of ovary*** - A **benign cystic teratoma** of the ovary is a germ cell tumor that typically does **not cause hormonal changes** leading to vaginal bleeding. - While it can cause symptoms such as **abdominal pain** or a palpable mass, it is not directly associated with postmenopausal vaginal bleeding. *Carcinoma of cervix* - **Cervical cancer** is a well-known cause of both **intermenstrual** and **postmenopausal vaginal bleeding**, especially following intercourse. - The abnormal growth of cells on the cervix can be fragile and bleed easily, leading to the symptom. *Senile vaginitis* - Also known as **atrophic vaginitis**, this condition occurs due to the **thinning and inflammation** of the vaginal walls due to decreased estrogen levels after menopause. - The fragile, dry tissues can easily tear and bleed, leading to postmenopausal bleeding or spotting. *Prolapse of uterus with decubitus ulcer* - A **decubitus ulcer** can form on the prolapsed cervix or vaginal wall due to **chronic friction and irritation**, particularly in cases of severe uterine prolapse. - The raw, ulcerated surface readily **bleeds**, especially with minor trauma or straining, causing postmenopausal vaginal bleeding.

Question 69: Menopause is associated with the following except:

A. Delusion (Correct Answer)
B. Loss of libido
C. Ischemic heart disease
D. Osteoporosis

Explanation: ***Delusion*** - Delusions are a feature of **psychotic disorders** and are not directly associated with the physiological changes of menopause. - While menopause can affect mood and cognitive function, it does not typically cause **psychotic symptoms** like delusions. *Loss of libido* - The decline in **estrogen levels** during menopause can lead to vaginal dryness and discomfort during intercourse, which can contribute to a loss of libido. - Hormonal changes also directly impact sexual desire, making it a common menopausal symptom. *Ischemic heart disease* - Estrogen has a **cardioprotective effect**, and its decline after menopause increases women's risk for **ischemic heart disease**. - The absence of estrogen contributes to changes in lipid profiles and endothelial function, predisposing women to cardiovascular events. *Osteoporosis* - Estrogen plays a crucial role in maintaining **bone density**, and its reduction during menopause accelerates bone loss. - This loss of bone mass significantly increases the risk of **osteoporosis** and fractures in postmenopausal women.

Question 70: A 58 year old woman, post menopausal for last 8 years comes with history of spotting per vaginum. What is the most likely cause?

A. Endometrial hyperplasia
B. Atrophic vaginitis (Correct Answer)
C. Endometrial carcinoma
D. Estrogen replacement therapy

Explanation: ***Atrophic vaginitis*** - **Most common cause** of postmenopausal bleeding, accounting for **60-70% of cases**. - Due to **decreased estrogen levels** after menopause, the vaginal epithelium and endometrium become thin, dry, and fragile. - This leads to **easy bleeding** from minimal trauma, presenting as spotting. - In a woman 8 years postmenopausal, atrophic changes are the statistically most likely cause. *Endometrial carcinoma* - **Must always be ruled out** in any woman with postmenopausal bleeding - this is the golden rule. - Accounts for approximately **10% of postmenopausal bleeding cases**. - While statistically less common than atrophy, requires investigation with **endometrial biopsy or transvaginal ultrasound**. - Risk factors include obesity, nulliparity, late menopause, and unopposed estrogen exposure. *Endometrial hyperplasia* - Results from **unopposed estrogen stimulation** causing excessive endometrial growth. - More commonly presents with **heavier or prolonged bleeding** rather than spotting. - Less likely in a woman 8 years postmenopausal without hormone therapy. - Can be a precursor to endometrial carcinoma if left untreated. *Estrogen replacement therapy* - Can cause **breakthrough bleeding or spotting** if used. - The question stem does not mention the patient is on hormone replacement therapy. - If present, would be an important consideration in the differential diagnosis.

Practice by Chapter

Physiology of Menopause

Practice Questions

Perimenopausal Transition

Practice Questions

Menopausal Symptoms and Management

Practice Questions

Hormone Replacement Therapy

Practice Questions

Non-hormonal Management Options

Practice Questions

Osteoporosis Prevention and Management

Practice Questions

Cardiovascular Health in Menopause

Practice Questions

Urogenital Atrophy

Practice Questions

Psychological Aspects of Menopause

Practice Questions

Premature Menopause

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?